VeriChip Corporation (Nasdaq: CHIP), a provider of RFID systems
for healthcare and patient-related needs, announced today it added
18 diabetic patients to its VeriMed Patient Identification System
at an Atlanta Diabetes EXPO sponsored by the American Diabetes
Association (ADA).
At the Diabetes EXPO, physicians implanted VeriMed RFID microchips
in conference attendees who signed up for the voluntary procedure.
The VeriMed Patient Identification System, which utilizes an implantable
RFID microchip in combination with a handheld RFID scanner and
a secure patient database, provides immediate access to important
health information for patients who arrive at an emergency department
unable to communicate.
Scott R. Silverman, Chairman and CEO of VeriChip, commented,
"We believe the VeriMed Patient Identification System is
an essential health care solution for at-risk patients, including
diabetics, who tend to present with various co-morbidities and
medications, and are more frequently admitted to emergency departments.
Since the inception of the VeriMed System, we always knew that
the diabetic community was in need of a way to communicate their
medical information better and more frequently. We will continue
to focus on diabetics and to enhance our relationship further
with the American Diabetes Association. The Atlanta Diabetes EXPO
provides us direct access so we can continue to educate an important
target audience."
The Diabetes EXPO is a patient-driven tradeshow, including professional
speakers and a variety of ADA program/event information, where
exhibitors from pharmaceutical and medical device companies display
beneficial products for diabetics. The Diabetes EXPO began in
1995 in Phoenix, Arizona, and has grown to 18, metro, major and
mid-size cities around the U.S. The next event will be held in
Boston on March 17, 2007.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida,
develops, markets and sells radio frequency identification, or
RFID, systems used to identify, locate and protect people and
assets. VeriChip's goal is to become the leading provider of RFID
systems for people in the healthcare industry. VeriChip sells
passive RFID systems for identification purposes and active RFID
systems for local-area location and identification purposes. VeriChip
recently began to market its VeriMed(TM) Patient Identification
System for rapidly and accurately identifying people who arrive
in an emergency room and are unable to communicate. This system
uses the first human-implantable passive RFID microchip, the implantable
VeriChip(TM), cleared for medical use in October 2004 by the United
States Food and Drug Administration.
VeriChip Corporation is majority-owned by Applied Digital Inc.
(Nasdaq: ADSX), which also owns a majority position in Digital
Angel Corporation (Amex: DOC).
Statements about the Company's future expectations, including
future revenues and earnings, and all other statements in this
press release other than historical facts are "forward-looking
statements" within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934,
and as that term is defined in the Private Litigation Reform Act
of 1995. Such forward-looking statements involve risks and uncertainties
and are subject to change at any time, and the Company's actual
results could differ materially from expected results. The Company
undertakes no obligation to update forward-looking statements
to reflect subsequently occurring events or circumstances.
